MedPath

Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy

Not Applicable
Completed
Conditions
Cow's Milk Allergy
Interventions
Other: New Amino Acid formula
Other: Commercially available Amino Acid Formula
Registration Number
NCT02414243
Lead Sponsor
Laboratorios Ordesa
Brief Summary

This is a prospective, controlled, multi-country study to verifying the hypoallergenicity of the new amino acid-based formula in infants and children aged\< 12 years with documented cow's milk protein allergy (CMPA).

Detailed Description

Not Provided

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
41
Inclusion Criteria
  • Children with documented cow's milk allergy, confirmed by one of the following criteria, within six months prior to study start (visit 2):

    • Positive double-blind, placebo-controlled oral food challenge (DBPCFC) with cow's milk OR
    • Positive open or single-blind oral food challenge with cow's milk carried out under the supervision of a specialist in children with clear immediate reactions and a positive test for specific IgE (in serum [sIgE>0,35 KUI/L] or skin prick test [SPT ≥ 3 mm]) OR
    • Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and detectable serum milk-specific IgE or positive skin prick test
  • Aged ≤12 years of age at screening.

  • Expected consumption of a minimum of 250ml of study formula per day during the open challenge.

  • Written informed consent from one or both parents (depending on the local legislation) or legal representative.

Exclusion Criteria
  • Children who receive breastfeeding at study enrolment.
  • Had any chronic medical diseases, chromosomal or major congenital anomalies, or major gastrointestinal disease/abnormalities (other the CMPA); had immunodeficiency; antihistamine [excluding eye drops] use in 7 days prior to a food challenge or oral steroid use within 14 days prior to enrolment; unstable asthma; severe uncontrolled eczema;
  • Severe anaphylactic reaction [required ≥ 2 doses of epinephrine] to milk or breast milk within the past 2 years;
  • Existing illness that could interfere with formula acceptance or identification of allergic reactions.
  • Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.
  • Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
New Amino Acid formulaNew Amino Acid formulaNew Amino-Acid based Infant Formula
Control formulaCommercially available Amino Acid FormulaCommercially available Amino Acid Formula
Primary Outcome Measures
NameTimeMethod
Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula14 days

To demonstrate that the test formula does not cause immediate and/or delayed allergic reactions to a double blind placebo control food challenge (DBPCFC) and/or a subsequent open food challenge (OFC). Incidence of immediate and/or delayed allergic reactions to the DBPCFC with the study product and/or active comparator and/or during the subsequent OPEN challenge phase of the study.

Secondary Outcome Measures
NameTimeMethod
Cow's Milk Allergy Related Symptoms14 days

Cow's Milk Allergy related Symptoms recorded at visit 1 and visit 4 using the Vandenplas symptom-based score (SBS).

The scoring ranges from 0 to 33. Each symptom has a maximal score of 6, except respiratory symptoms where the maximal score is 3. If final score ≥ 12, the symptoms are likely cow's milk related. This could potentially be CMPA.

If final score \<12, the symptoms are less likely related to cow's milk. Look for other causes.

Trial Locations

Locations (1)

Ospedale Pediatrico Bambino Gesù

🇮🇹

Rome, Italy

© Copyright 2025. All Rights Reserved by MedPath